Latest 10-K annual reports
NYSE
Boston Beer Company reports a 4.7% volume decrease in 2025 but achieves significant net income growth and improved gross margins, driven by cost efficiencies and strategic brand focus.
NYSE
Globus Medical achieved significant revenue and net income growth in 2025, driven by strategic acquisitions and new product launches, despite ongoing legal and regulatory challenges.
NASDAQ
PDF Solutions reported a 22% increase in total revenues to $219.0 million for 2025, driven by the SecureWise acquisition and strong Volume-based revenue, despite recording a net loss of $0.6 million.
NASDAQ
Cardiff Oncology's latest 10-K reveals promising clinical trial data for onvansertib in mCRC and mTNBC, but highlights significant financial challenges and a going concern warning.
CCC Intelligent Solutions Holdings Inc. reported a 11.9% increase in revenue for fiscal year 2025, driven by existing customer upgrades, new solution offerings, and the acquisition of EvolutionIQ, despite a significant drop in net income.
NASDAQ
Ziff Davis, a digital media and internet company, reported a 3.5% revenue increase in 2025, alongside declining net income, significant goodwill impairments, and ongoing high-profile legal challenges.
NASDAQ
Marqeta, a modern card issuing platform, reported a 23% increase in net revenue to $624.9 million and a net loss of $13.9 million for the fiscal year ended December 31, 2025, driven by strong TPV growth and strategic acquisitions.
NYSE
NVRI
Enviri CORPEnviri Corporation's 2025 financial results show a significant drop in operating income and increased net loss, despite a strategic agreement to sell its Clean Earth segment for over $3 billion.
NYSE
Black Stone Minerals, L.P. reported increased net income and total revenue for 2025, driven by higher natural gas prices and derivative gains, despite a decline in overall production and oil prices.
BYON
Beyond, INCBed Bath & Beyond, Inc. reports a 25% revenue decrease in 2025, alongside improved gross margins and ongoing strategic transformations including a pending merger with The Brand House Collective.
NASDAQ
Alphatec Holdings, Inc. announced a 25% increase in total revenue to $764.2 million for the fiscal year ended December 31, 2025, driven by surgeon adoption and product portfolio expansion.
NASDAQ
Commerce Bancshares, Inc. reported a 7.6% increase in net income for 2025, driven by revenue growth and a strategic acquisition, while maintaining robust capital levels.
NASDAQ
Keurig Dr Pepper Inc. reported a significant increase in net income and diluted EPS for 2025, driven by strong refreshment beverage performance and reduced impairment charges, while preparing for a transformative JDE Peet's acquisition and subsequent business separation.
NYSE
CNO Financial Group's 2025 net income declined significantly due to one-time charges, though operating income saw a modest increase, driven by strong premium collections and strategic business exits.
NASDAQ
Palomar Holdings, a specialty insurer, announced significant premium growth and profitability in 2025, driven by strategic acquisitions and product diversification.
NASDAQ
BridgeBio Pharma, Inc. reports significant commercial uptake for Attruby and positive Phase 3 clinical trial results for multiple pipeline candidates, despite continued net losses.
NYSE
Wells Fargo & Company announced a significant increase in net income and diluted earnings per share for 2025, alongside the removal of its asset growth limitation by the Federal Reserve Board.
NYSE
LTC Properties, Inc. reports its 2025 annual results, highlighting a strategic shift to a Seniors Housing Operating Portfolio (SHOP) model, significant property transactions, and a write-off of effective interest receivable.
NASDAQ
Verra Mobility Corporation announced a significant 11.4% increase in total revenue for fiscal year 2025, reaching $979.1 million, alongside successful debt refinancing and a substantial rise in net income.
NYSE
Range Resources Corporation reported a significant increase in net income and production for 2025, driven by higher realized prices and strategic capital investments, while also increasing dividends and repurchasing shares.
NYSE
PNR
Pentair PLCPentair plc delivered robust financial performance in 2025 with increased net sales, gross profit, and diluted EPS, alongside a significant dividend hike and new share repurchase authorization.
NYSE
Truist Financial Corporation announced a significant increase in net income for 2025, driven by loan and deposit growth, and authorized a new $10 billion share repurchase program.
NASDAQ
HSIC
Henry Schein INCHenry Schein reports 4.0% net sales growth in 2025, navigating the residual impact of a 2023 cyber incident and preparing for a CEO transition while advancing its BOLD+1 strategic plan.
NASDAQ
BELFA
Bel Fuse INC /NJBel Fuse Inc. reported a significant increase in net sales and gross profit for 2025, driven by strong demand in aerospace, defense, and networking, and the full-year contribution of the Enercon acquisition, despite an impairment charge for its Innolectric investment.
NASDAQ
Kiniksa Pharmaceuticals International, plc reported significant product revenue growth in 2025, driven by ARCALYST sales, while advancing its pipeline with KPL-387 and KPL-1161.
NASDAQ
AbCellera Biologics Inc. reported a 161% revenue increase and reduced net loss in 2025, driven by a patent settlement and clinical pipeline advancements.
NYSE
Luxfer Holdings PLC reported a decrease in net sales but an increase in adjusted net income for 2025, driven by strategic divestitures and operational improvements despite softness in some end-markets.
NASDAQ
PCVX
Vaxcyte, INCVaxcyte initiated multiple Phase 3 trials for its 31-valent pneumococcal vaccine candidate, VAX-31, following positive Phase 1/2 results and expanded Breakthrough Therapy Designation, while also raising $632.5 million in a public offering.
NASDAQ
CBLL
Ceribell, INCCeriBell, Inc. announced a 36% revenue increase to $89.1 million in 2025, driven by expanded adoption of its AI-powered Ceribell System and new FDA clearances for delirium and pediatric/neonatal seizure monitoring, despite continued net losses.
NASDAQ
VERX
Vertex, INCVertex, Inc. announced a significant turnaround to net income in 2025, alongside robust revenue growth and strategic investments in AI and global e-invoicing solutions, despite a slight dip in customer retention metrics.